Numinus subsidiary files U.S. patent application for rapid production of psychedelic treatments

The Vancouver-based company has a licence from Health Canada to test, sell, and distribute psychedelic substances.

psychedelic products, Numinus, Numinus Wellness

Photo by Fly:D


A Vancouver-based psychedelics company hopes that a new invention will scale up the creation of psychedelic products. In order to achieve this, Numinus Bioscience Inc. has filed a U.S. patent application for a proprietary rapid production process.

According to the publicly traded parent company, Numinus Wellness Inc., this “sustainable, reproducible and easily scalable process will be used to rapidly generate therapeutic products from psychoactive fungi species”.

These psychedelic products include psilocybin and other psychoactive compounds. Moreover, a growing body of research suggests that they could be used in conjunction with psychotherapy in the treatment of mental illness and mental disorders.

Numinus Wellness has a goal of supporting widespread access to psychedelic-assisted psychotherapy.

“The rapid production process announced today meets that goal by enhancing our ability to seamlessly forumate safe and effective products with consistent psychoactive properties at scale, with the regulatory confidence that comes with standardized products,” said Sharan Sichu, the general manager and science officer at Numinus Bioscience.

The parent company has a licence from Health Canada to test, sell, and distribute psychedelic substances.

Psychedelic products could help in many areas

Researchers at various universities have been investigating the efficacy of psychedelic products in the treatment of posttraumatic stress disorder and treatment-refractory depression.

In addition, researchers are examining the effects of psychedelic products on alcohol and nicotine addiction.

“It’s not a cure for everybody,” Numinus chief medical officer Dr. Evan Wood told CannCentral last year. “But in comparison to the best available treatments we have for alcohol or nicotine addiction—and there’s some work being done in cocaine addiction as well—the rates of remission are pretty dramatic over the best available standard of care that we have to offer for those conditions. So it really looks like something is there.”

On June 18, Numinus graduated to Tier 1 on the TSX Venture Exchange based onn its historial financial performance, stated of development, and financial resources.

Numinus Wellness shares trade at $0.94 on the TSX Venture Exchange. The company’s market capitalization stands at $187.4 million.

Charlie Smith

I'm the editor of the Georgia Straight newspaper in Vancouver, as well as a CannCentral contributor.

Leave your opinion for the editor...We read everything!

Your email address will not be published.